Minimal residual disease detection with tumor-specific CD160 correlates with event-free survival in chronic lymphocytic leukemia

In chronic lymphocytic leukemia (CLL), the detection of minimal residual disease (MRD) correlates with outcome in the trial setting. However, MRD assessment does not guide routine clinical management and its assessment remains complex. We incorporated detection of the B cell, tumor-specific antigen...

Descripción completa

Detalles Bibliográficos
Autores principales: Farren, T W, Giustiniani, J, Fanous, M, Liu, F, Macey, M G, Wright, F, Prentice, A, Nathwani, A, Agrawal, S G
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2015
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4314455/
https://www.ncbi.nlm.nih.gov/pubmed/25615279
http://dx.doi.org/10.1038/bcj.2014.92

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4314455/
https://www.ncbi.nlm.nih.gov/pubmed/25615279
http://dx.doi.org/10.1038/bcj.2014.92

Ejemplares similares